Physician
West Hills Pathology Consultants
West Hills Pathology Consultants was paid $318K by Medicaid between Jan 2018 and Dec 2024, across 77 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 15% of everything it billed.
33Billing provider infoWEST HILLS PATHOLOGY CONSULTANTS
WEST HILLS, CA 91307
WEST HILLS, CA 91307
33aNPI1558737320assigned 08/17/2015
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$318K
24GClaims295,293
24DCodes billed77
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in California
Rank by total paid#73 of 222
Median peer was paid$42K
This provider vs. median7.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,425 | $53K | |
| 2019 | 43,564 | $44K | |
| 2020 | 35,841 | $41K | |
| 2021 | 48,301 | $57K | |
| 2022 | 36,846 | $35K | |
| 2023 | 44,112 | $53K | |
| 2024incomplete | 37,204 | $34K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 15% | 46,240 | 33,669 | $49K |
| 85027 | 15% | 59,340 | 37,546 | $48K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.3% | 4,724 | 2,489 | $26K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 4.8% | 738 | 701 | $15K |
| 84484 | 4.6% | 14,445 | 12,518 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.3% | 14,031 | 6,978 | $14K |
| 85730 | 3.4% | 15,534 | 13,558 | $11K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.4% | 1,166 | 1,090 | $11K |
| 83880 | 3.4% | 3,201 | 2,913 | $11K | |
| 83735 | 3.1% | 11,557 | 5,683 | $10K | |
| 83690 | 3.0% | 14,206 | 12,675 | $10K | |
| 85060 | 3.0% | 1,292 | 1,200 | $9K |
65 more codes
| 87040 | 2.8% | 4,254 | $9K | |
| 81001 | 2.6% | 24,503 | $8K | |
| 85610 | 1.9% | 14,216 | $6K | |
| 83605 | 1.8% | 3,737 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 2,142 | $4K |
| 84100 | <1% | 6,501 | $3K | |
| 87186 | <1% | 2,708 | $3K | |
| 87077 | <1% | 2,459 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,888 | $3K |
| 84702 | <1% | 2,104 | $3K | |
| 87631 | <1% | 477 | $3K | |
| 84703 | <1% | 4,894 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,606 | $3K |
| 81025 | <1% | 2,827 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 279 | $2K |
| 80061 | Lipid panel | <1% | 1,288 | $2K |
| 80074 | <1% | 341 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,434 | $2K |
| 87070 | <1% | 1,329 | $2K | |
| 85379 | <1% | 1,535 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,494 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 66 | $2K |
| 82803 | <1% | 825 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,674 | $1K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 47 | $1K |
| 80202 | <1% | 688 | $1K | |
| 86901 | <1% | 4,345 | $1K | |
| 86900 | <1% | 4,226 | $1K | |
| 88304 | <1% | 74 | $1K | |
| 86850 | <1% | 2,125 | $832.86 | |
| 88312 | <1% | 54 | $739.62 | |
| 86140 | <1% | 955 | $619.34 | |
| 80076 | <1% | 837 | $612.31 | |
| 84134 | <1% | 238 | $508.45 | |
| 82550 | <1% | 538 | $495.53 | |
| 82728 | <1% | 349 | $438.40 | |
| 84145 | <1% | 99 | $414.33 | |
| 83550 | <1% | 428 | $379.66 | |
| 83540 | <1% | 472 | $363.26 | |
| 82248 | <1% | 595 | $291.52 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 41 | $255.54 |
| 85007 | <1% | 860 | $227.70 | |
| 83615 | <1% | 350 | $226.09 | |
| 85652 | <1% | 721 | $218.82 | |
| 84132 | <1% | 607 | $216.46 | |
| 82746 | <1% | 129 | $198.23 | |
| 86756 | <1% | 157 | $181.35 | |
| 87088 | <1% | 209 | $125.93 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 58 | $110.84 |
| 81003 | <1% | 581 | $93.58 | |
| 87075 | <1% | 74 | $90.52 | |
| 82607 | <1% | 71 | $85.73 | |
| 84439 | <1% | 106 | $73.14 | |
| 85384 | <1% | 66 | $67.41 | |
| 86920 | <1% | 54 | $63.41 | |
| 87205 | <1% | 86 | $52.44 | |
| 82140 | <1% | 18 | $29.31 | |
| 82272 | <1% | 14 | $11.20 | |
| 82150 | <1% | 16 | $7.27 | |
| 87184 | <1% | 19 | $5.55 | |
| 87210 | <1% | 14 | $5.32 | |
| 87806 | <1% | 29 | $5.29 | |
| 84550 | <1% | 12 | $2.59 | |
| 80320 | 0% | 804 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 72 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAWLINSON, NEIL (PARTNER)